156 related articles for article (PubMed ID: 18298332)
1. Development of multivalent radioimmunonanoparticles for cancer imaging and therapy.
Natarajan A; Xiong CY; Gruettner C; DeNardo GL; DeNardo SJ
Cancer Biother Radiopharm; 2008 Feb; 23(1):82-91. PubMed ID: 18298332
[TBL] [Abstract][Full Text] [Related]
2. NanoFerrite particle based radioimmunonanoparticles: binding affinity and in vivo pharmacokinetics.
Natarajan A; Gruettner C; Ivkov R; DeNardo GL; Mirick G; Yuan A; Foreman A; DeNardo SJ
Bioconjug Chem; 2008 Jun; 19(6):1211-8. PubMed ID: 18517234
[TBL] [Abstract][Full Text] [Related]
3. Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding.
Xiong CY; Natarajan A; Shi XB; Denardo GL; Denardo SJ
Protein Eng Des Sel; 2006 Aug; 19(8):359-67. PubMed ID: 16760193
[TBL] [Abstract][Full Text] [Related]
4. Development of tumor targeting bioprobes ((111)In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy.
DeNardo SJ; DeNardo GL; Miers LA; Natarajan A; Foreman AR; Gruettner C; Adamson GN; Ivkov R
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7087s-7092s. PubMed ID: 16203807
[TBL] [Abstract][Full Text] [Related]
5. Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct.
Kelly MP; Lee FT; Tahtis K; Power BE; Smyth FE; Brechbiel MW; Hudson PJ; Scott AM
Cancer Biother Radiopharm; 2008 Aug; 23(4):411-23. PubMed ID: 18771345
[TBL] [Abstract][Full Text] [Related]
6. Development of a hyperimmune anti-MUC-1 single chain antibody fragments phage display library for targeting breast cancer.
Winthrop MD; DeNardo SJ; DeNardo GL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3088s-3094s. PubMed ID: 10541348
[TBL] [Abstract][Full Text] [Related]
7. Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF--induced thermoablative therapy for human breast cancer in mice.
DeNardo SJ; DeNardo GL; Natarajan A; Miers LA; Foreman AR; Gruettner C; Adamson GN; Ivkov R
J Nucl Med; 2007 Mar; 48(3):437-44. PubMed ID: 17332622
[TBL] [Abstract][Full Text] [Related]
8. Triple Therapy of HER2
Zolata H; Afarideh H; Davani FA
Cancer Biother Radiopharm; 2016 Nov; 31(9):324-329. PubMed ID: 27831759
[TBL] [Abstract][Full Text] [Related]
9. Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers.
Albrecht H; Denardo GL; Denardo SJ
Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):304-13. PubMed ID: 17464275
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody conjugated magnetic nanoparticles could target MUC-1-positive cells in vitro but not in vivo.
Shanehsazzadeh S; Gruettner C; Lahooti A; Mahmoudi M; Allen BJ; Ghavami M; Daha FJ; Oghabian MA
Contrast Media Mol Imaging; 2015; 10(3):225-36. PubMed ID: 25327822
[TBL] [Abstract][Full Text] [Related]
11. The fate of MAb-targeted Cd(125m)Te/ZnS nanoparticles in vivo.
Kennel SJ; Woodward JD; Rondinone AJ; Wall J; Huang Y; Mirzadeh S
Nucl Med Biol; 2008 May; 35(4):501-14. PubMed ID: 18482688
[TBL] [Abstract][Full Text] [Related]
12. 99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma.
Goel A; Baranowska-Kortylewicz J; Hinrichs SH; Wisecarver J; Pavlinkova G; Augustine S; Colcher D; Booth BJ; Batra SK
J Nucl Med; 2001 Oct; 42(10):1519-27. PubMed ID: 11585867
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.
DeNardo SJ; Richman CM; Albrecht H; Burke PA; Natarajan A; Yuan A; Gregg JP; O'Donnell RT; DeNardo GL
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7187s-7194s. PubMed ID: 16203820
[TBL] [Abstract][Full Text] [Related]
14. Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals.
Natarajan A; Xiong CY; Albrecht H; DeNardo GL; DeNardo SJ
Bioconjug Chem; 2005; 16(1):113-21. PubMed ID: 15656582
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts.
Pavlinkova G; Beresford GW; Booth BJ; Batra SK; Colcher D
J Nucl Med; 1999 Sep; 40(9):1536-46. PubMed ID: 10492377
[TBL] [Abstract][Full Text] [Related]
16. Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy.
Winthrop MD; DeNardo SJ; Albrecht H; Mirick GR; Kroger LA; Lamborn KR; Venclovas C; Colvin ME; Burke PA; DeNardo GL
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3845S-53S. PubMed ID: 14506182
[TBL] [Abstract][Full Text] [Related]
17. [Anti-tumor effect of lentivirus-mediated MUCI antibody-targeted gene therapy with VP22-TK system on MUC1(+) human ovarian cancer transplanted intraperitoneally in nude mice].
Kong B; Wang W; Liu C; Ma D; Qu X; Jiang J; Yang X; Zhang Y; Jiang S
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(17):1207-10. PubMed ID: 12475412
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
[TBL] [Abstract][Full Text] [Related]
19. A new radiopharmaceutical compound (131I-PR81) for radioimmunotherapy of breast cancer: labeling of antibody and its quality control.
Mohammadnejad J; Rasaee MJ; Babaei MH; Paknejad M; Zahir MH; Salouti M; Rajabi AB; Mazidi M
Hum Antibodies; 2010; 19(4):79-88. PubMed ID: 21178279
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.
Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J; Kosteiny SA; Gansow OA; Nelson DL
Cancer Res; 1994 Aug; 54(16):4362-70. PubMed ID: 8044783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]